Clinical trials: Type 1 Diabetes With Diabetic Macular Edema
Diabetic Macular Edema, Type 1 Diabetes Mellitus
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
The primary objective of the study is to determine if treatment with high-dose aflibercept (HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA) compared to aflibercept dosed every 8 weeks.
- Conditions
- Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Trial name
- PHOTON (NCT04429503)
- Testing
- aflibercept, High-dose aflibercept
- Where
- 138 sites in United States, Canada and 6 more
- Volunteers
- 660 people
- Sponsor
- Regeneron Pharmaceuticals